Proteomic Analysis of Circulating Monocytes Identifies Cathepsin D as A Potential Novel Plasma Marker of Acute Coronary Syndromes

  1. Jiménez-Narcher, Julio 1
  2. Alvarez-Llamas, Gloria 2
  3. Vivanco, Fernando 23
  4. Barderas, Maria G. 4
  5. Blanco-Colio, Luis Miguel 1
  6. Dardé, Verónica M. 24
  7. de la Cuesta, Fernando 2
  8. Martin-Ventura, Jose Luis 1
  9. Lopez-Bescos, Lorenzo 5
  10. Tuñó, José 6
  11. Egido, Jesús 1
  1. 1 Vascular Research Laboratory, Fundació Jiménez Díaz, Autóoma University, Madrid
  2. 2 Department of Immunology, Fundació Jiménez Díaz, Autóoma University, Madrid
  3. 3 Proteomic Unit, Universidad Complutense, Madrid, Spain.
  4. 4 Vascular Pathophysiology, Hospital Nacional de Paraplejicos, SESCAM, Toledo.
  5. 5 Fundació Hospital de Alcorcó, Madrid, Spain
  6. 6 Department of Cardiology, Fundació Jiménez Díaz, Autóoma University, Madrid;
Mostrar afiliaciones +
Revista:
Clinical medicine. Cardiology

ISSN: 1178-1165

Año de publicación: 2008

Volumen: 2

Páginas: CMC.S654

Tipo: Artículo

DOI: 10.4137/CMC.S654 GOOGLE SCHOLAR lock_openAcceso abierto editor

Otras publicaciones en: Clinical medicine. Cardiology

Resumen

We have performed a proteomic analysis of peripheral blood monocytes from ACS patients in comparison withhealthy subjects and stable coronary patients in order to search novel biomarkers of ACS in circulating monocytes. Monocyteswere isolated from blood of patients with non-ST elevation ACS (n = 27) at day 0, 2 and 6 months, and from patients withstable coronary disease (n = 10) and matched healthy controls (n = 11). The proteomic analysis of monocytes from ACSpatients at day 0 showed that cathepsin D is differentially expressed compared to healthy subjects and stable coronarypatients. Western blot analysis indicated that the mature form of cathepsin D at day 0 was overexpressed in monocytes ofACS patients in relation to healthy subjects. In contrast, the precursor of this enzyme, absent at day 0 in ACS patients, washighly expressed in monocytes of healthy subjects. Furthermore, the upregulation of the mature form of cathepsin Ddiminished along the time, while the expression of the precursor increased. ACS patients also showed signifi cantly increasedplasma cathepsin D levels on admission compared to healthy subjects and stable patients. Cathepsin D plasma levelsdiminished at 2 and 6 months to control values. Finally, cathepsin D levels were independent of the existence of coronaryrisk factors and CRP levels, correlating only with CD40L. Since this protease participates in the genesis and rupture ofatherosclerotic plaques, it could represent a potential marker of ACS.